>>Are we expecting another Perlegen announcement on Monday ??<<
Which Monday, Nigel? Today they announce two to make up for missing one last week.
>>MOUNTAIN VIEW, Calif., Dec. 18 /PRNewswire/ -- Perlegen Sciences, Inc., a privately-held genetics company, announced today that it has entered into a research collaboration with Eli Lilly and Company (NYSE: LLY - News). Perlegen will use its proprietary high-resolution whole genome association technologies and over 1.5 million Perlegen-identified single nucleotide polymorphisms (SNPs) to identify genetic markers for Lilly.
Lilly will provide Perlegen with undisclosed research funding and potential milestone payments and royalties. Perlegen will also obtain certain rights to develop products including novel therapeutics based on the research results. As part of the research collaboration, Lilly will make an equity investment in Perlegen.
"We look forward to using Perlegen's technologies to accelerate the development of important therapeutics and diagnostics for Lilly through high-resolution whole genome scanning," said Brad Margus, CEO of Perlegen. "This kind of research will apply Perlegen's capabilities to improving the lives of patients."<<
snip
>>MOUNTAIN VIEW, Calif., Dec. 20 /PRNewswire/ -- Perlegen Sciences, Inc., a privately-held genetics company, announced today a research collaboration with Pfizer Inc to discover the human genetic contributions to cardiovascular disease. The goal of the collaboration is to identify variations in DNA that bring about cardiovascular disease, and to use those genetic discoveries to enable the research and development of new pharmaceutical and diagnostic products.
Perlegen will employ its high-density genotyping technologies and knowledge of human genetic variation to identify genes and other genetic loci associated with cardiovascular disease. Financial terms of the collaboration were not disclosed.
Cardiovascular disease is the leading cause of death in the Western world, and is expected to become the leading cause of death worldwide by 2020. In the United States, almost one million people die of cardiovascular disease each year, and about 61 million live with this disease.
"Identifying the primary genetic determinants of cardiovascular disease promises to accelerate the search for new pharmaceutical agents that act on the causes of this global killer," said Brad Margus, CEO of Perlegen. "We are pleased to collaborate with Pfizer, a leader in the research and development of drugs that effectively treat cardiovascular disease.">>
snip
Cheers, Tuck |
